Search - tctmd.com

Displaying 121 - 140 of 173

Sort: Relevancy | Date

Presentation TVT 2017

Featured Lecture: The Spectrum of Bioprosthetic Valve Leaflet Thrombosis: From "Subclinical" Leaflet Thickening to Hemodynamic Changes and Clinical Events

Presenter: David W.M. Muller, Lars Sondergaard

June 16, 2017

News Conference News EuroPCR 2017

If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year

Shelley Wood

May 17, 2017

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Shelley Wood

May 12, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

News Daily News

Leaflet Thickening, Valve Durability After Balloon-Expandable TAVR: Studies Offer New Insights

Todd Neale

December 26, 2016

Presentation TCT 2016

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

Presenter: Raj Makkar, Lars Sondergaard

October 31, 2016

Presentation TCT 2016

TCT 79: Course of Early Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement With or Without Oral Anticoagulation

Presenter: John M. Lasala, Philippe Pibarot, Jürgen Rothe

October 31, 2016

Presentation TCT 2016

Leaflet Thickening, Dysfunction, and Thrombosis: Clinical Perspectives- Are Problems Under-Reported? Are the Changes a Class Effect?

Presenter: Carlos E. Ruiz, Ulrich Steinseifer, Raj Makkar

October 30, 2016

Presentation TCT 2016

Leaflet Thickening, Dysfunction, and Thrombosis: Latest Recommendations by the ISO Cardiac Valves Committee

Presenter: Carlos E. Ruiz, Ulrich Steinseifer

October 30, 2016

Presentation TCT 2016

Case #3: Leaflet Thrombosis Following Transcatheter Valve-in-Valve: Could It Have Been Prevented?

Presenter: Stanley J. Chetcuti, Susheel K. Kodali, Isaac George

October 30, 2016

News Conference News PCR London Valves 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

News Conference News PCR London Valves 2016

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

Shelley Wood

September 20, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Conference News ESC 2016

Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy

Todd Neale

September 02, 2016

News Conference News TVT 2016

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Michael O'Riordan

June 18, 2016

Presentation TVT 2016

An Update on Subclinical Bioprosthetic Leaflet Thickening and Thrombosis: Possible Effects on TAVR Durability

Presenter: Raj Makkar

June 17, 2016

News Features

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Caitlin E. Cox

June 17, 2016

Advertisement

Featured Lecture: The Spectrum of Bioprosthetic Valve Leaflet Thrombosis: From "Subclinical" Leaflet Thickening to Hemodynamic Changes and Clinical Events

If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Live From Washington: ACC 2017, Day Three

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Leaflet Thickening, Valve Durability After Balloon-Expandable TAVR: Studies Offer New Insights

Controversy 2. Global Clinical Trial Experiences on Bioprosthetic Leaflet Thickening/Thrombosis: Updates and Insights

TCT 79: Course of Early Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement With or Without Oral Anticoagulation

Leaflet Thickening, Dysfunction, and Thrombosis: Clinical Perspectives- Are Problems Under-Reported? Are the Changes a Class Effect?

Leaflet Thickening, Dysfunction, and Thrombosis: Latest Recommendations by the ISO Cardiac Valves Committee

Case #3: Leaflet Thrombosis Following Transcatheter Valve-in-Valve: Could It Have Been Prevented?

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

An Update on Subclinical Bioprosthetic Leaflet Thickening and Thrombosis: Possible Effects on TAVR Durability

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content